Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Single-Arm Study of ATG-010 Plus Dexamethasone in Patients With Multiple Myeloma Refractory to Prior Treatment With Immunomodulatory Agents and Proteasome Inhibitor

NCT03944057 is registered in ClinicalTrials.gov with Antengene Corporation as lead sponsor.

NCT NCT03944057
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03944057 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Single-Arm Study of ATG-010 Plus Dexamethasone in Patients With Multiple Myeloma Refractory to Prior Treatment With Immunomodulatory Agents and Proteasome Inhibitor
Lead sponsor
Antengene Corporation
Phase
Phase 2
Overall status
Completed
Start date
September 2, 2019
Completion date
February 25, 2022
Enrollment
82 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

relapse/refractory multiple myeloma